All News

Top news of the day from across the health care landscape.

Two cell mutations have been linked to acute myeloid leukemia, but the reason for their cooperation has been unknown.

Just as vaccinations get under way in full force, a few indicators raise the question about whether the vaccine really is as well matched as was anticipated.

The funding is awarded to health departments representing 57 geographic areas to expand treatment and prevention efforts for HIV/AIDS.

The newly published guidelines answer 16 core questions about the diagnosis and treatment of CAP in adults. The guidelines are more narrow in scope than previous versions and focus primarily on the care of a patient with active pneumonia.

The black-white disparity in breast cancer mortality has remained stable since 2011 after widening over the past 3 decades.

The FDA has approved emtricitabine 200 mg and tenofovir alafenamide 25 mg (Descovy, Gilead Sciences Inc.) as a second pre-exposure prophylaxis drug in at-risk adults and adolescents weighing at least 75 Ib.

Study offers a new perspective on the molecular events that may lead some individuals to develop multiple sclerosis.

Top news of the day from across the health care landscape.

The PREVENT trial revealed that secukinumab demonstrated both efficacy and a favorable safety profile for patients with non-radiographic axial spondyloarthritis (nr-axSpA).

Findings published in the CDC’s Morbidity and Mortality Weekly Report (MMWR) suggest that THC products are playing a role in the recent outbreak of lung injuries associated with e-cigarette and vape use.

The National Institute on Aging (NIA) has launched 2 new research centers, the Alzheimer Centers for the Discovery of New Medicines, designed to diversify and strengthen the Alzheimer disease drug development pipeline.

Top news of the day from across the health care landscape.

Two lawsuits against the FDA have been resolved in a conclusion favorable to Endo International, which argued that vasporessin should be excluded from the agency’s compounding list.

Niraparib (Zejula) found to prolong time without symptoms or toxicity in patients with ovarian cancer.

Oprah Winfrey’s message is clear: the flu and pneumonia vaccines are important.

Johnson & Johnson and its Janssen Pharmaceutical Cos unit have agreed to a more than $10 million settlement, rather than allowing the matter go to federal trial.

The FDA’s accelerated approval program has been criticized recently for pushing drugs into the market before they undergo randomized phase 3 clinical trials.

Many critics have accused Oliver of oversimplifying a complex issue.

Rite Aid has officially launched the annual Pharmacy Champions program, which is held every October during American Pharmacists Month.

Study shows the importance of a cancer-causing oncogene, known as SET/TAF1, in triggering cancer cell proliferation.

The National Institute of Allergy and Infectious Diseases (NIAID), which is a part of the National Institute of Health, has developed the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program.

Officials from the FDA have granted Geron Corporation’s imetelstat fast track designation for adult patients with intermediate-2 or high-risk myelofibrosis (MF) whose disease has relapsed after or is refractory to janus kinase (JAK) inhibitor treatment.

Researchers from John Hopkins Medicine have successfully used microscopic man-made particles to help predict early signs of severe chronic obstructive pulmonary disease (COPD) in patients.

Seventeen million children and adults in the United States are currently living with ADHD. Each October, ADHD Awareness Month is celebrated with different events, activities, and resources to continue shining the light on the disorder.

Top news of the day from across the health care landscape.

Fulvestrant injection treats certain types of breast cancer in post-menopausal women who were not previously treated with endocrine therapy and as a combination for advanced or metastatic breast cancer.

Why is a young patient using a topical steroid for vitiligo?